| Q41347995 | Bystander signaling via oxidative metabolism |
| Q93339046 | Carborane-Based Analogues of 5-Lipoxygenase Inhibitors Co-inhibit Heat Shock Protein 90 in HCT116 Cells |
| Q37963769 | Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention |
| Q37995534 | Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke |
| Q37046636 | Emerging treatment of atopic dermatitis |
| Q36108432 | Fatty acid oxidation in the pathogenesis of Alzheimer's disease |
| Q30513559 | Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium. |
| Q38977139 | Novel cinnamic acid derivatives as antioxidant and anticancer agents: design, synthesis and modeling studies. |
| Q35332873 | Resolvins and protectins in inflammation resolution. |
| Q40394553 | Role of cysteinyl leukotriene receptor-1 antagonists in treatment of experimentally induced mammary tumor: does montelukast modulate antitumor and immunosuppressant effects of doxorubicin? |
| Q38785505 | The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target |
| Q37016080 | The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field |
| Q36572139 | What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? |